Comparison Overview

Octapharma Plasma, Inc.

VS

Torrent Pharmaceuticals Ltd

Octapharma Plasma, Inc.

10644 Westlake Drive, Charlotte, NC, US, 28273
Last Update: 2025-12-11

About Us: Octapharma Plasma, Inc. helps change lives through the incredible power of plasma donation. Backed by a global organization and supported by a dedicated team of more than 5,000 employees across the United States, we operate over 175 centers nationwide. Our mission is clear — “To be the leading plasma donation company in unmatched service to our donors, communities, and employees.” What We Do: • Collect and Test Plasma: Ensuring the highest standards in plasma collection and testing to create life-saving medications. • Support Patients Globally: Through our parent company, Octapharma AG (Switzerland), we develop treatments for Hematology, Immunotherapy, and Critical Care, benefiting patients in 113 countries. Why Join Us: At Octapharma Plasma, we live by our core values of Respect, Collaboration, Innovation, and Excellence. We offer professional growth, access to cutting-edge tools, collaborative teams, and career paths tailored to your aspirations. Our Vision: To improve the quality of life of everyone we serve through the life-changing power of plasma. Join Our Team: Explore opportunities with Octapharma Plasma and become part of a team making a global impact. Visit our Careers page to see how your talents can contribute to our mission. Learn more about our parent company and worldwide impact at www.octapharmaplasma.com.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 3,050
Subsidiaries: 0
12-month incidents
2
Known data breaches
2
Attack type number
2

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd, Ashram road, Ahmedabad, Gujarat, IN, 380015
Last Update: 2025-12-11
Between 750 and 799

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,324
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/octapharma-plasma-inc..jpeg
Octapharma Plasma, Inc.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/torrent-pharmaceuticals-ltd.jpeg
Torrent Pharmaceuticals Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Octapharma Plasma, Inc.
100%
Compliance Rate
0/4 Standards Verified
Torrent Pharmaceuticals Ltd
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

Octapharma Plasma, Inc. has 150.0% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Torrent Pharmaceuticals Ltd in 2025.

Incident History — Octapharma Plasma, Inc. (X = Date, Y = Severity)

Octapharma Plasma, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Torrent Pharmaceuticals Ltd (X = Date, Y = Severity)

Torrent Pharmaceuticals Ltd cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/octapharma-plasma-inc..jpeg
Octapharma Plasma, Inc.
Incidents

Date Detected: 11/2025
Type:Breach
Motivation: Financial gain (potential identity theft, fraud)
Blog: Blog

Date Detected: 8/2025
Type:Ransomware
Motivation: Financial gain through ransom payments
Blog: Blog

Date Detected: 4/2024
Type:Breach
Blog: Blog
https://images.rankiteo.com/companyimages/torrent-pharmaceuticals-ltd.jpeg
Torrent Pharmaceuticals Ltd
Incidents

No Incident

FAQ

Torrent Pharmaceuticals Ltd company demonstrates a stronger AI Cybersecurity Score compared to Octapharma Plasma, Inc. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Octapharma Plasma, Inc. company has historically faced a number of disclosed cyber incidents, whereas Torrent Pharmaceuticals Ltd company has not reported any.

In the current year, Octapharma Plasma, Inc. company has reported more cyber incidents than Torrent Pharmaceuticals Ltd company.

Octapharma Plasma, Inc. company has confirmed experiencing a ransomware attack, while Torrent Pharmaceuticals Ltd company has not reported such incidents publicly.

Octapharma Plasma, Inc. company has disclosed at least one data breach, while the other Torrent Pharmaceuticals Ltd company has not reported such incidents publicly.

Neither Torrent Pharmaceuticals Ltd company nor Octapharma Plasma, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Octapharma Plasma, Inc. company nor Torrent Pharmaceuticals Ltd company has reported experiencing or disclosing vulnerabilities publicly.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Octapharma Plasma, Inc. company nor Torrent Pharmaceuticals Ltd company has publicly disclosed detailed information about the number of their subsidiaries.

Torrent Pharmaceuticals Ltd company employs more people globally than Octapharma Plasma, Inc. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds SOC 2 Type 1 certification.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds SOC 2 Type 2 certification.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds ISO 27001 certification.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds PCI DSS certification.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds HIPAA certification.

Neither Octapharma Plasma, Inc. nor Torrent Pharmaceuticals Ltd holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H
Description

Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.

Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:N
Description

Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.

Risk Information
cvss3
Base: 8.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:H/I:H/A:L
Description

The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Risk Information
cvss3
Base: 5.4
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:L/A:N